Milrinone和多巴酚丁胺均为兼有周围血管扩张作用的正性肌力药物。本试验表明,持续静脉给药可迅速且持久地改善慢性充血性心力衰竭(CHF)患者血流动力状态,两药的效果基本相同。虽然两药的不良作用较为少见,但有可能引起严重心律失常,尤以Milrinone为然,切不可掉以轻心。受试者为病情稳定至少2周的慢性CHF患者,心功能NYHAⅢ～Ⅳ级,心脏指数≤2.5L/min/m~2或肺动脉楔压≥15mmHg。无一例近期(3个月内)心肌梗塞,心绞痛限制运动,不稳定型心绞痛或严重心律失常。79例受试者随机分成2组。M组40(男35、女5)例静脉给予Milrinone,首先推注负荷剂量 Milrinone and dobutamine are both inotropic agents that have peripheral vasodilation. This study shows that continuous intravenous administration can rapidly and lastingly improve the hemodynamic status of patients with chronic congestive heart failure (CHF), the effect of the two drugs are basically the same. Although the adverse effects of the two drugs are less common, they can cause serious arrhythmias, especially Milrinone, and must not be taken lightly. Subjects were chronic CHF patients with stable disease for at least 2 weeks, NYHA III-IV cardiac function, cardiac index ≤ 2.5 L / min / m 2, or pulmonary artery wedge pressure ≥ 15 mm Hg. None of the recent (3 months) myocardial infarction, angina restricted exercise, unstable angina or severe arrhythmia. 79 subjects were randomly divided into two groups. M group 40 (male 35, female 5) cases of intravenous Milrinone, the first bolus load dose